These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16012795)

  • 1. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
    Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
    Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.
    Chang SM; Kuhn J; Wen P; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; Cloughesy T; De Angelis L; Razier J; Hess K; Dancey J; Prados MD;
    Invest New Drugs; 2004 Nov; 22(4):427-35. PubMed ID: 15292713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
    Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
    Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
    Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
    Chheda MG; Wen PY; Hochberg FH; Chi AS; Drappatz J; Eichler AF; Yang D; Beroukhim R; Norden AD; Gerstner ER; Betensky RA; Batchelor TT
    J Neurooncol; 2015 Feb; 121(3):627-34. PubMed ID: 25503302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
    Sarkaria JN; Galanis E; Wu W; Dietz AB; Kaufmann TJ; Gustafson MP; Brown PD; Uhm JH; Rao RD; Doyle L; Giannini C; Jaeckle KA; Buckner JC
    Clin Cancer Res; 2010 Nov; 16(22):5573-80. PubMed ID: 20921209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
    Kesavabhotla K; Schlaff CD; Shin B; Mubita L; Kaplan R; Tsiouris AJ; Pannullo SC; Christos P; Lavi E; Scheff R; Boockvar JA
    J Exp Ther Oncol; 2012; 10(1):71-81. PubMed ID: 22946346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
    Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
    J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
    Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR
    J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
    J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
    Mason WP; Macneil M; Kavan P; Easaw J; Macdonald D; Thiessen B; Urva S; Lwin Z; McIntosh L; Eisenhauer E
    Invest New Drugs; 2012 Dec; 30(6):2344-51. PubMed ID: 22160854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
    Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S
    Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.